Fredrik Dalborg, CEO and Group President of Boule Diagnostics, has decided to leave the company and continue his career with new assignments outside the Group in another Swedish medical technology company. Fredrik will remain in his role during his period of notice.
For further information, please contact:
Peter Ehrenheim, Chairman of the Board, Boule Diagnostics AB, phone. + 46 706-67 57 11
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 08:00 CET on July 22, 2019.